Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2004-12-16
2011-11-22
Long, Scott (Department: 1633)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C977S906000, C514S04400A
Reexamination Certificate
active
08062669
ABSTRACT:
A vectorization and delivery system of therapeutic or diagnostic substances including (i) at least one polymer and (ii) at least one nontoxic positively charged polysaccharide, the nanoparticles having a substantially homogeneous distribution of size.
REFERENCES:
patent: 3632754 (1972-01-01), Balassa et al.
patent: 4474769 (1984-10-01), Smith
patent: 4913908 (1990-04-01), Couvreur et al.
patent: 5830883 (1998-11-01), Block et al.
patent: 2 649 321 (1991-01-01), None
patent: 2 649 321 (1991-01-01), None
patent: 2 724 935 (1996-03-01), None
patent: 2 724 935 (1996-03-01), None
patent: WO 96/24377 (1996-08-01), None
patent: WO99/43359 (1999-09-01), None
patent: WO 99/43359 (1999-09-01), None
Yang et al (Colloid Polym. Sci., 2000. 278: 285-292).
Lee et al. (J. Pharm. Sciences, Jul. 2000. vol. 89, No. 7: 850-866).
Gombotz et al. (Bioconjugate Chem. 1995, 6: 332-351).
Couvreur et al (J Pharm Pharmacol. May 1979; 31(5): 331-332).
Schroeder et al. (Peptides 1998. 19(4): 777-780).
Vijayanathan et al. (Biochemistry. Dec. 3, 2002, 41(48): 14085-14094).
Hans et al. (Current Opinion in Solid State and Materials Science. 2002; 6: 319-327).
Cui et al. (Journal of Controlled Release. 2001; 75: 409-419, published online Jul. 30, 2001).
Hu et al. (Biomaterials. 2002; 23: 3193-3201, available online Mar. 19, 2002).
P. Couvreur et al., “Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties”, J. Pharm. Pharmacol., (1979), vol. 31, pp. 331 and 332.
S.C. Yang et al., “Formation of positively charged poly(butyl cyanoacrylate) nanoparticles stabilized with chitosan”, Colloid Polym Sci., (2000), vol. 278, pp. 285-292.
H.-P. Zobel et al., “Cationic Polyhexylcyanoacrylate Nanoparticles as Carriers for Antisense Oligonucleotides:”, Antisense & Nucleic Acid Drug Development, (1997) vol. 7, pp. 483-493.
Olivier Zelphati et al., “Lipsomes as a carrier for intracellular delivery of antisense oligonucleotides: a real or magic bullet?” Journal of Controlled Release, vol. 41, (1996), pp. 99-119.
James M. Wilson et al., Correction of CD18-Deficient Lymphocytes by Retrovirus-Mediated Gene Transfer, Science, vol. 248, Jun. 1990, pp. 1413-1414.
George Y. Wu et al., “Receptor-mediated in Vitro Gene Transformation by a Soluble DNA Carrier System” , The Journal of Biological Chemistry, vol. 262, No. 10, Issue of Apr. 5, 1987, pp. 4429-4432.
Mary X. Tang et al., “In Vitro Gene Delivery by Degraded Polyamidoamine Dendrimers”, Bioconjugate Chem., (1966), vol. 7, pp. 703-714.
Inder M. Verma et al., “Gene therapy-promises, problems and prospects”, Nature, (Sep. 18, 1997), vol. 389, pp. 239-242.
Simon C.W. Richardson et al., Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA, International Journal of Pharmaceutics, vol. 178, (1999), pp. 231-243.
C.K. Rha et al., “Novel Applications of Chitosan”, Hemisphere Publishing, Washington, (1984), pp. 285-311.
Jean-Serge Remy et al., “Gene transfer with liposermines and polyethylenimines”, Advanced Drug Delivery Reviews; (1998), vol. 30, pp. 85-95.
Pilar Calvo et al., “Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines”, Pharmaceutical Research, (1997), vol. 14, No. 10, pp. 1431-1436.
Russell J. Mumper et al., “Polyvinyl Derivatives as Novel Interactive Polymers for Controlled Gene Delivery to Muscle”, Pharmaceutical Research, (1996), vol. 13. No. 5, pp. 701-709.
Richard A. Morgan et al., “Human Gene Therapy”, Annu. Rev. Biochem., (1993), vol. 62, pp. 191-217.
Fred D. Ledley, “Non-viral gene therapy”, Current Opinion in Biotechnology, (1994), vol. 5, pp. 626-636.
D.D. Lasic et al., “Liposomes in gene therapy”, Advanced Drug Delivery Reviews, (1996), vol. 20, pp. 221-266.
Jan Knapczyk et al. “Pharmaceutical Dosage Forms With Chitosan”, Elsevier Applied Science, London, (1984), pp. 665-669.
Alexander V. Kabanov et al., “Micelles of amphiphilic block copolymers as vehicles for drug delivery”, BioAlliance Pharma, (Date?), pp. 347-376.
Shigehiro Hirano et al., “Chitosan: A Biocompatible Material for Oral and Intravenous Administrations”, Plenum Press, NY (1990), pp. 283.
Ira W. Hillyard et al., “Antacid and Antiulcer Properties of the Polysaccharide Chitosan in the Rat”, P.S.E.B.M., (1964), vol. 115, pp. 1108-1112.
Ellen F. Fynan et al., “DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations”, Proc. Natl. Acad. Sci. USA, Immunology, (Dec. 1993), vol. 90, pp. 11478-11482.
G. Fradet et al., “Evaluation of Chitosan as a New Hemostatic Agent: In Vitro and In Vivo Experiments”, Plenum Press, NY, (1986), pp. 443-451.
Rocio Fernandez-Urrusuno et al., “Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles”, Pharmaceutical Research, (1999). vol. 16, No. 10.
Philip L. Felgner, “Particulate systems and polymers for in vitro and in vivo delivery of polynucleotides”, Advanced Drug Delivery Reviews, (1990), vol. 5, pp. 163-187.
Patrick Erbacher el al., “Chitosan-Based Vector/DNA Complexes for Gene Delivery; Biophysical Characteristics and Transfection Ability” Pharmaceutical Research, (1998), vol. 15. No. 9, pp. 1332-1339.
J.T. Douglas et al., “Targeted gene therapy”, Tumor Targeting, (1995), vol. 1, pp. 67-84.
S.T. Crooke, “Delivery of Oligonucleotides and Polynucleotides”, Journal of Drug Targeting, (1995), vol. 3, pp. 185-190.
Christine Chavany et al., “Polyalkylcyanoacrylate Nanoparticles as Polymeric Carriers for Antisense Oligonucleotides”, Pharmaceutical Research, (1992), vol. 9, No. 4, pp. 441-449.
Thomas Chandy et al., “Chitosan—As a Biomaterial”, Biomat., Art. Cells, Art. Org., (1990), vol. 18 (1), pp. 1-24.
Otmane Boussif et al., “A versatile vector for gene and oligonucleotide transfer into cells in culture and In vivo: Polyethylenimine”, Proc. Natl. Acad. Sci., USA,, Biochemistry, (Aug. 1995), vol. 92, pp. 7297-7301.
Jean-Paul Behr et al., Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA, Proc. Natl. Acad. Sci. USA, (Sep. 1989), vol. 86, pp. 6982-6986.
P. Calvo et al., “Oligonucleotide—Chitosan Nanoparticles As New Gene Therapy Vector”, Proc. 2ndWorld Meeting APG1/APV, Paris, (May 25/28, 1998), pp. 111-1112.
Kobayashi, T. et al., “Effect of Chitosan on Serum and Liver Cholesterol Levels in Cholesterol-Fed Rats,”Nutrition Reports International, Mar. 1979, vol. 19, No. 3, pp. 327-334.
Kreuter, J., “Nanoparticles,”J. Colloidal Drug Delivery Systems, Marcel Decker, New York, 1994, pp. 219-342.
Struszczyk, H. et al., “Biodegradability of Chitosan Fibres,”Elsevier Applied Science, 1991, pp. 580-585.
Roberts, G.A.F., “Structure of Chitin and Chitosan,”Chitin Chemistry, G.A.F. Roberts, ed., Houndsmills, England, Macmillan, 1992, Chapter 1, pp. 1-53.
Roberts, G.A.F., “Solubility and Solution Behavior of Chitin and Chitosan,”Chitin Chemistry, G.A.F. Roberts, ed., Houndsmills, England, Macmillan, 1992, Chapter 6, pp. 274-329.
Aboubakar Malam
Chaumont Christine
Maksimenko Andrei
Polard Valérie
Bioalliance Pharma
DLA Piper (LLP) US
Long Scott
LandOfFree
Vectorization system comprising nanoparticles of homogenous... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vectorization system comprising nanoparticles of homogenous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vectorization system comprising nanoparticles of homogenous... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4310878